Your CDMO Project starts here.
Meet us at CPHI 2025 - Frankfurt
Join us to discuss about your key CDMO challenges: scalability, flexibility, quality, time-to-market, and innovation.
The LFB Biomanufacturing team will be at the booth to talk about your projects and share our bioproduction expertise.
A perfect opportunity to build strong connections and explore tailor-made solutions together.
The LFB Biomanufacturing team will be at the booth to talk about your projects and share our bioproduction expertise.
A perfect opportunity to build strong connections and explore tailor-made solutions together.
Connecting at the heart of Pharma Innovation
LFB Biomanufacturing will be present from October 28 to 30, 2025, at Messe Frankfurt for CPHI Frankfurt 2025 — the leading international event for the pharmaceutical industry, bringing together more than 62,000 visitors, 2,400 exhibitors from over 166 countries, along with a rich program of 100+ content sessions and 200 expert speakers.
Join us in the Bioproduction zone, a dedicated area for biotechnologies, biologics, and biosimilars, where we will be pleased to share our CDMO expertise, our Cell Line & Development platforms, and GMP Manufacturing whether clinical or commercial for your projects.
Our Experts, Your Partners
Herbert joined LFB in 2022, as Director of the Alès Site, and then moved on to become Managing Director of LFB BIOMANUFACTURING, in 2023.
An environmental engineer by training, Herbert continued his studies to improve his skills in the field of Biotechnologies. He obtained his doctorate in biochemistry and cellular and molecular biotechnology, followed by a postgraduate diploma in biology, biochemistry and biotechnology at the ESTBB School for Biotechnology Engineering.
He was part of the team of the pharmaceutical company GSK for 10 years, and began his career by creating the Quality Department at the group's Belgian site. He then led several regulatory and remediation projects, resulting in the lifting of an FDA warning letter in Canada and the restoration of production performance in Italy in particular. Following an acquisition, he led the operational strategy for a key GSK Consumer Healthcare site before with was spun off in Switzerland.
After 10 years working abroad, he returned to France and joined the LFB Group, taking over the management of the bioproduction site in Alès, in the Gard department.
An environmental engineer by training, Herbert continued his studies to improve his skills in the field of Biotechnologies. He obtained his doctorate in biochemistry and cellular and molecular biotechnology, followed by a postgraduate diploma in biology, biochemistry and biotechnology at the ESTBB School for Biotechnology Engineering.
He was part of the team of the pharmaceutical company GSK for 10 years, and began his career by creating the Quality Department at the group's Belgian site. He then led several regulatory and remediation projects, resulting in the lifting of an FDA warning letter in Canada and the restoration of production performance in Italy in particular. Following an acquisition, he led the operational strategy for a key GSK Consumer Healthcare site before with was spun off in Switzerland.
After 10 years working abroad, he returned to France and joined the LFB Group, taking over the management of the bioproduction site in Alès, in the Gard department.
David joined LFB Biomanufacturing in 2014 as head of manufacturing, then join in 2023 the commercial operation as Business Development Director.
Graduated in Biotechnology engineering and Microbiology (Agro Paris Tech), David has more than 29 years of experience in manufacturing, process development and scale up of recombinant medicinal proteins. David started his career at Sanofi in Process Development then in commercial Production in bacterial manufacturing (antibiotics and steroids). He developed his experience in recombinant protein manufacturing at Merck Serono following the development of more than 10 recombinant proteins and monoclonal antibodies. Moving as head of Process development within Merck Serono then Merck Millipore, he worked on Monoclonal manufacturing Platform, Technology transfer, Single Use Processes implementation and development of recombinant protein processes (Hormone, Mabs and Fc-Fusion).
David joined LFB Biomanufacturing in 2014 as head of manufacturing to start the new manufacturing Unit (UP2) in 2016 and prepare the approval of the LFB biotechnology Manufacturing unit for the FVII Coagulation factor Drug Substance.
From 2014 to 2023, he led the development and/or production of 21 biomolecules and participated to the FDA/EMA registration of the FVII Coagulation factor Drug Substance.
In 2023, David move to a Business position as as Business Development Director for LFB Biomanufacturing.
Graduated in Biotechnology engineering and Microbiology (Agro Paris Tech), David has more than 29 years of experience in manufacturing, process development and scale up of recombinant medicinal proteins. David started his career at Sanofi in Process Development then in commercial Production in bacterial manufacturing (antibiotics and steroids). He developed his experience in recombinant protein manufacturing at Merck Serono following the development of more than 10 recombinant proteins and monoclonal antibodies. Moving as head of Process development within Merck Serono then Merck Millipore, he worked on Monoclonal manufacturing Platform, Technology transfer, Single Use Processes implementation and development of recombinant protein processes (Hormone, Mabs and Fc-Fusion).
David joined LFB Biomanufacturing in 2014 as head of manufacturing to start the new manufacturing Unit (UP2) in 2016 and prepare the approval of the LFB biotechnology Manufacturing unit for the FVII Coagulation factor Drug Substance.
From 2014 to 2023, he led the development and/or production of 21 biomolecules and participated to the FDA/EMA registration of the FVII Coagulation factor Drug Substance.
In 2023, David move to a Business position as as Business Development Director for LFB Biomanufacturing.
Fanny joined LFB Biomanufacturing in 2025 as Business Development Director.
A biologist by training, she completed her studies with a Master's degree in Marketing Management for the Health Industry at Toulouse Business School.
Fanny leverages extensive experience in the health industry, spanning sales, training, and marketing.
After many years in research and diagnostics, working with private labs and hospitals, she moved into the CDMO environment as Area Sales Manager at Novasep, focusing on biomolecule purification, gene therapy, monoclonal antibodies, and ADC production.
She played an active role in establishing Pierre Fabre's CDMO offering, dedicated to the manufacture of mAbs and ADCs at the production unit located in Saint-Julien-en-Genevois, France.
Following the acquisition of the site at the end of 2020 by the French group FAREVA, one of the world leaders in industrial subcontracting, Fanny continued to develop the site while successfully managing internal and external collaborations.
Building on this experience, Fanny joined LFB to support the growth of the Alès site, dedicated to CDMO activities for the purification of biological molecules, recombinant proteins, monoclonal antibodies, and bispecific antibodies.
A biologist by training, she completed her studies with a Master's degree in Marketing Management for the Health Industry at Toulouse Business School.
Fanny leverages extensive experience in the health industry, spanning sales, training, and marketing.
After many years in research and diagnostics, working with private labs and hospitals, she moved into the CDMO environment as Area Sales Manager at Novasep, focusing on biomolecule purification, gene therapy, monoclonal antibodies, and ADC production.
She played an active role in establishing Pierre Fabre's CDMO offering, dedicated to the manufacture of mAbs and ADCs at the production unit located in Saint-Julien-en-Genevois, France.
Following the acquisition of the site at the end of 2020 by the French group FAREVA, one of the world leaders in industrial subcontracting, Fanny continued to develop the site while successfully managing internal and external collaborations.
Building on this experience, Fanny joined LFB to support the growth of the Alès site, dedicated to CDMO activities for the purification of biological molecules, recombinant proteins, monoclonal antibodies, and bispecific antibodies.
